(3-methylpyridin-1-ium-1-yl)amide | 59046-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3-methylpyridin-1-ium-1-yl)amide
• 英文别名: 3-methylpyridine N-imine；(3-Methylpyridin-1-ium-1-yl)azanide
• CAS: 59046-22-9
• 化学式: C₆H₈N₂
• 分子量: 108.143
• InChiKey: DVOKWSKPVHKEBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  4.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3-methylpyridin-1-ium-1-yl)amide 在 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 17.0h， 生成 5-methyl-N-(3,6-dihydro-1(2H)-pyridinyl)benzamide
  参考文献：
  名称：

  Synthesis of N-(3,6-dihydro-1(2H)-pyridinyl)benzamides with hyperglycemic-hypoglycemic activity

  摘要：

  A group of N-(3,6-dihydro-1(2H)-pyridinyl)benzamides 7 were synthesized to determine the effect that the position and physicochemical properties of substituents attached to the heterocyclic ring have on blood glucose levels. 5-Methyl-N-(3,6-dihydro-1(2H)-pyridinyl)benzamide 7b was the most active hyperglycemic agent, elevating blood glucose 124% and 116% at 2 and 4 h, respectively, after a 100 mg/kg po dose. The most active hypoglycemic agent was the 4-acetyl analogue 7o, which was about 50% as active as chlorpropamide, lowering blood glucose 19% at 4 h after a 100 mg/kg po dose. A correlation between blood glucose levels and the partition coefficient P was not observed.

  DOI：

  10.1021/jm00384a018
• 作为产物：
  描述：

  3-甲基吡啶 在 hydroxylamine-O-sulfonic acid 作用下， 以 水 为溶剂， 反应 0.5h， 生成 (3-methylpyridin-1-ium-1-yl)amide
  参考文献：
  名称：

  [EN] FACTOR IXa INHIBITORS
  [FR] INHIBITEURS DU FACTEUR IXA

  摘要：

  本发明提供了一种Formula I的化合物，以及包括一种或多种该化合物的药物组合物，以及使用该化合物用于治疗或预防不稳定性心绞痛、难治性心绞痛、心肌梗死、短暂性缺血性发作、心房颤动、血栓性中风、栓塞性中风、深静脉血栓形成、弥散性血管内凝血、眼部纤维蛋白堆积、以及再闭塞或再狭窄的再通血管的方法。这些化合物是选择性因子IXa抑制剂。

  公开号：

  WO2016133793A1

文献信息

• Synthesis of pyridine N-imine complexes of methylcobaloxime and reactions of bis(dimethylglyoximato)methyl(Pyridine N-imine)cobalt with acid anyhydrides and acetylenedicarboxylic acid dimethyl ester
  作者：Yasushi Tsurita、Taro Saito、Yukiyoshi Sasaki

  DOI：10.1016/s0022-328x(00)81386-8

  日期：1980.12

  Pyridine N-imine complexes of methylcobaloxime, CH3Co(Hdmg)2(R1— C5HnN+N−H) (n = 4; R1 = H, 2-CH3, 3-CH3, 4-CH3: n = 3; R1 = 2,6-CH3), have been synthesized by the reaction of CH3Co(Hdmg)2S(CH3)2 with a pyridine N-imine which is generated from a pyridine, hydroxylamine-O-sulfonic acid and K2CO3. The reactions of CH3Co(Hdmg)2(C5H5N+N−H) with acid anhydrides form new methylcobaloxime complexes with N-substituted

  吡啶Ñ methylcobaloxime的-亚胺配合物，CH 3的Co（Hdmg）2（R 1 - Visual C 5 ħ Ñ Ñ + N - H）（Ñ = 4; R 1 = H，2-CH 3，3-CH 3， 4-CH 3：n = 3； R 1 = 2,6-CH 3），是通过CH 3 Co（Hdmg）2 S（CH 3）2与吡啶N-亚胺的反应合成的吡啶，羟胺-O-磺酸和K 2 CO 3。CH 3 Co（Hdmg）2（C 5 H 5 N + N - H）与酸酐的反应与N-取代的吡啶N-亚胺形成新的甲基钴肟配合物，CH 3 Co（Hdmg）2（C 5 H 5 N + N - R 2）R 2 = COPh，COMe，COEt）。与马来酸酐，（吡啶N生成-丙烯酰亚胺基羧酸。用乙炔二羧酸二甲酯，配体的1，3-偶极环加成得到吡唑并[1，5-a]吡啶-2，3-二羧酸二甲酯。
• 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
  申请人：FISONS CORPORATION

  公开号：EP0540318A1

  公开（公告）日：1993-05-05

  Compounds of formula I, wherein    A represents C=C, S or O;    Q represents a 5- or 6-membered unsaturated heterocyclic ring having a nitrogen atom in the position adjacent to the point of attachment, 0-3 further heteroatoms selected from N, O and S, and substituents R⁶ and R⁷;    R¹ represents H or C₁₋₆ alkyl;    R² represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₆ cycloalkyl or NH₂CH₂CO-; in addition, R¹ and R² taken together may form a C₃₋₅ alkylene chain;    R³ represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl;    R⁴ and R⁵ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl or NR⁸R⁹;    R⁶ and R⁷ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl, C₁₋₆ hydroxyalkyl, amidino, CONH₂ or NR⁸R⁹;    in addition, R⁶ and R⁷ may independently represent O when substituted on N;    R⁸ and R⁹ independently represent H or C₁₋₆ alkyl;    with various provisos;    and pharmaceutically acceptable derivatives thereof;    are useful as pharmaceuticals, in particular in the treatment of neurological disorders.

  式 I 的化合物、 其中 A 代表 C=C、S 或 O； Q 代表 5 或 6 元不饱和杂环，该杂环在邻近连接点的位置有一个氮原子，0-3 个选自 N、O 和 S 的杂原子，以及取代基 R⁶ 和 R⁷； R¹ 代表 H 或 C₁₋₆ 烷基； R² 代表 H、C₁₋₆ 烷基、C₃₋₆ 烯基、C₃₋₆ 炔基、C₃₋₆ 环烷基或 NH₂CH₂CO-；此外，R¹ 和 R² 合在一起可形成 C₃₋₅亚烷基链； R³ 代表 H、C₁₋₆ 烷基、C₃₋₆ 烯基、C₃₋₆ 炔基； R⁴ 和 R⁵ 各自代表 H、OH、C₁₋₆ 烷氧基、C₁₋₆ 烷基、卤素、三氟甲基或 NR⁸R⁹； R⁶ 和 R⁷ 独立地代表 H、OH、C₁₋₆ 烷氧基、C₁₋₆ 烷基、卤素、三氟甲基、C₁₋₆ 羟烷基、脒基、CONH₂ 或 NR⁸R⁹； 此外，当 R⁶ 和 R⁷ 被 N 取代时，可独立地代表 O； R⁸ 和 R⁹ 独立地代表 H 或 C₁₋₆ 烷基； 具有各种但书； 及其药学上可接受的衍生物； 可用作药物，特别是用于治疗神经系统疾病。
• Synthesis of 2- and 2,3-Substituted Pyrazolo[1,5-<i>a</i>]pyridines: Scope and Mechanistic Considerations of a Domino Direct Alkynylation and Cyclization of <i>N</i>-Iminopyridinium Ylides Using Alkenyl Bromides, Alkenyl Iodides, and Alkynes
  作者：James J. Mousseau、James A. Bull、Carolyn L. Ladd、Angélique Fortier、Daniela Sustac Roman、André B. Charette

  DOI：10.1021/jo201303x

  日期：2011.10.21

  Direct functionalization and tandem processes have both received considerable recent interest due to their cost and time efficiency. Herein we report the synthesis of difficult to obtain 2-substituted pyrazolo[1,5-a]pyridines through a tandem palladium-catalyzed/silver-mediated elimination/direct functionalization/cyclization reaction involving N-benzoyliminopyridinium ylides. As such, these biologically important molecules are prepared in an efficient, high-yielding manner, only requiring a two-step sequence from pyridine. Aryl-substituted alkenyl bromides and iodides are effective ylide coupling partners. Mechanistic studies led to the use of terminal alkynes, which extended the scope of the reaction to include alkyl substitution on the unsaturated reactive site. The optimization, scope, and mechanistic considerations of the process are discussed.
• FUJITO H.; TOMINAGA Y.; MATSUDA Y.; KOBAYASHI G., HETEROCYCLES, 1977, 6, NO 4, 379-382
  作者：FUJITO H.、 TOMINAGA Y.、 MATSUDA Y.、 KOBAYASHI G.

  DOI：——

  日期：——